Legal & General Group Plc Increases Stake in Veeva Systems Inc.

The investment firm now owns 939,884 shares of the technology company's stock worth $280 million.

Mar. 12, 2026 at 10:21am

Legal & General Group Plc, a major investment management firm, has increased its stake in Veeva Systems Inc. (NYSE:VEEV) by 4.5% during the third quarter. The firm now owns 939,884 shares of the technology company's stock, worth approximately $280 million, making it one of Veeva's largest institutional investors.

Why it matters

Veeva Systems is a leading provider of cloud-based software solutions for the global life sciences industry. As one of the company's largest shareholders, Legal & General Group's increased investment signals confidence in Veeva's long-term growth prospects and the continued demand for its industry-specific applications and data solutions.

The details

According to a recent SEC filing, Legal & General Group Plc purchased an additional 40,432 shares of Veeva Systems during the third quarter, bringing its total stake in the company to 939,884 shares. This represents approximately 0.57% of Veeva's outstanding shares and makes Legal & General one of the top institutional investors in the company.

  • Legal & General Group Plc increased its stake in Veeva Systems during the third quarter of 2026.

The players

Legal & General Group Plc

A major global investment management firm that has increased its stake in Veeva Systems to become one of the company's largest institutional investors.

Veeva Systems Inc.

A cloud software company that develops industry-specific applications and data solutions for the global life sciences sector.

Got photos? Submit your photos here. ›

The takeaway

Legal & General Group's increased investment in Veeva Systems reflects the firm's confidence in the company's long-term growth potential within the life sciences technology market. As one of Veeva's largest shareholders, Legal & General's stake signals that the investment firm believes Veeva's cloud-based solutions will continue to see strong demand from pharmaceutical, biotechnology, and other life sciences companies.